BiotechTube

SUSTOL

ApprovedUNKNOWN
0 watching 0 views this weekπŸ“ˆ Rising
77
Hype Score

Development Stage

βœ“
Pre-clinical
βœ“
Phase 1
βœ“
Phase 2
βœ“
Phase 3
5
Approved
Indication / Disease

Chemotherapy-Induced Nausea and Vomiting (CINV)

Conditions

Chemotherapy-Induced Nausea and Vomiting (CINV)

Trial Timeline

Jul 6, 2022 β†’ Oct 1, 2025

NCT ID
NCT05434663

About SUSTOL

SUSTOL is a approved stage product being developed by Heron Therapeutics for Chemotherapy-Induced Nausea and Vomiting (CINV). The current trial status is unknown. This product is registered under clinical trial identifier NCT05434663. Target conditions include Chemotherapy-Induced Nausea and Vomiting (CINV).

Hype Score Breakdown

Clinical
30
Activity
20
Company
2
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT05434663ApprovedUNKNOWN

Competing Products

20 competing products in Chemotherapy-Induced Nausea and Vomiting (CINV)

See all competitors
ProductCompanyStageHype Score
SON-080Sonnet BioTherapeuticsPhase 1/2
36
GranisetronKyowa KirinPhase 3
77
ONO-7746Ono PharmaceuticalPhase 1
33
ONO-2910 + PlaceboOno PharmaceuticalPhase 2
52
PROCRIT 40,000 IU QW + PlaceboJohnson & JohnsonPhase 2
52
Hetrombopag Olamine + Hetrombopag Olamine οΌ›Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3
77
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 2
52
Hetrombopag + Hetrombopag plus Placebo + PlaceboJiangsu Hengrui MedicinePhase 3
77
Hetrombopag + Matching placeboJiangsu Hengrui MedicinePhase 3
77
Hetrombopag + PlaceboJiangsu Hengrui MedicinePhase 3
77
Fosaprepitant dimeglumine + Fosaprepitant Placebo + Dexamethasone + Ondansetron + Dexamethasone Placebo + Ondansetron Placebo + Rescue TherapyMerckPhase 3
77
FosaprepitantMerckPhase 2
52
Fosaprepitant + Placebo for fosaprepitant + Ondansetron + Dexamethasone + 5-HT3 antagonistMerckPhase 3
77
Fosaprepitant + Dexamethasone + 5HT3MerckPhase 2
52
aprepitant + Comparator: Placebo to aprepitant + dexamethasone + granisetron + dexamethasoneMerckPhase 3
77
aprepitant + Comparator: ondansetron + Comparator: dexamethasone + Comparator: fosaprepitant dimeglumine + Comparator; Placebo (unspecified) + Comparator; Placebo (unspecified)MerckPhase 3
77
EMENDMerckPre-clinical
23
Fosaprepitant Dimeglumine + 5-HT3 antagonist + DexamethasoneMerckApproved
85
ondansetron clinical trial formulation + ondansetron marketed formulationMerckPhase 1
33
Aprepitant + Palonosetron + DexamethasoneMerckPhase 2
52

Other Products from Heron Therapeutics

HTX-011 + Bupivacaine Hydrochloride + Ibuprofen + AcetaminophenApproved
77
Bupivacaine HClApproved
77
HTX-011 + Bupivacaine Hydrochloride + Ibuprofen + AcetaminophenApproved
77
Bupivacaine liposome injectable suspension + Bupivacaine HCl without epinephrine via continuous infusionApproved
77
ZYNRELEF 200Mg-6Mg Extended-Release SolutionApproved
77